Welcome to our dedicated page for Livongo Health news (Ticker: LVGO), a resource for investors and traders seeking the latest updates and insights on Livongo Health stock.
The Livongo Health, Inc. (LVGO) news page on Stock Titan provides an archive of company-related announcements and media coverage from the period when LVGO traded on Nasdaq. Livongo was a digital health company that described itself as an Applied Health Signals provider, focused on helping people with chronic conditions such as diabetes, hypertension, weight issues, and behavioral health challenges live better and healthier lives.
News items for LVGO include quarterly financial results, updates on key operating metrics, and commentary from company leadership. For example, Livongo’s second and third quarter 2020 releases highlighted year-over-year revenue growth, increases in Livongo for Diabetes membership, client expansion, and the use of its Applied Health Signals platform and AI+AI engine to support consumer-directed virtual care.
Other coverage features strategic partnerships and distribution relationships. These include agreements with organizations such as GuideWell and its subsidiary Florida Blue, as well as partnerships for chronic kidney disease and behavioral health programs. Several articles also discuss Livongo’s pending merger agreement with Teladoc Health, including joint investor conference presentations and references to a joint proxy statement/prospectus filed with the SEC.
Investors and researchers can use this news archive to review how Livongo communicated its strategy, described its chronic condition programs, and positioned its role in virtual care and remote monitoring. Because the available items relate to a specific historical period and mention a proposed merger, this page is best viewed as a record of Livongo’s public narrative and business developments while the LVGO symbol was active.
Livongo Health (Nasdaq: LVGO) has revised its revenue forecast for Q2 2020 to between $86 million to $87 million, surpassing the previous estimate of <$b>73 million to $75 million. The increase includes approximately $2 million to $3 million of non-recurring items. CEO Zane Burke stated that the growth reflects the demand for Livongo's solutions, particularly during the COVID-19 pandemic, which enhances their appeal to major employers and health plans. The company will discuss these results further on a conference call scheduled for August 6, 2020.
Livongo Health announced findings from two studies demonstrating the effectiveness of its remote monitoring technologies in improving care for individuals with diabetes. Presented at the American Diabetes Association’s 80th Scientific Sessions, the first study highlighted predictors of emergency healthcare visits linked to hypo- and hyperglycemic events among 7,633 participants. The second study, involving 1,089 participants in collaboration with Eli Lilly, showed a correlation between platform utilization and improved diabetes management. Livongo's AI+AI engine continues to enhance personalized care by aggregating vital health data.
Livongo has announced the pricing of $475 million in 0.875% convertible senior notes due 2025, increasing from a previous offering of $400 million. The notes, general unsecured obligations, will accrue interest payable semiannually and can be converted into cash or stock. The company expects net proceeds to reach $461.1 million, earmarked for general corporate purposes and capped call transactions. The offering closes on June 4, 2020. Livongo's initial conversion price is set at $75.57 per share, reflecting a 27.5% premium over its June 1, 2020 closing price.
Livongo Health, Inc. (Nasdaq: LVGO) announced a private offering of $400 million in convertible senior notes due 2025, with an option for an additional $60 million. The notes, which will accrue interest and be convertible into cash and shares, aim to support Livongo's corporate purposes, including working capital and business development. Notably, the company plans capped call transactions to mitigate potential stock dilution. The offering is subject to market conditions, with no guarantee on completion. These notes are not registered under the Securities Act, affecting their sale capabilities.
MOUNTAIN VIEW, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc. (Nasdaq: LVGO) announced participation in several upcoming investor conferences. The events include the Jefferies Virtual Healthcare Conference on June 2 at 2:00 p.m. ET, the Stifel 2020 Virtual Cross Sector Insight Conference on June 10 at 10:00 a.m. ET, and the Goldman Sachs 41st Annual Global Healthcare Conference on June 10 at 3:50 p.m. ET. Webcasts of these presentations will be accessible in the Investor Relations section of the company’s website.
Livongo Health, a leader in Applied Health Signals, announced executive presentations at two key investor conferences on May 19, 2020. The conferences include the Needham Virtual Technology & Media Conference at 3:15 p.m. ET and the RBC Capital Markets Global Healthcare Virtual Conference at 4:50 p.m. ET. A live webcast of both presentations will be accessible via the Investor Relations section of Livongo's website. Livongo empowers individuals with chronic conditions, focusing on diabetes, hypertension, and more, through its innovative AI-driven health insights.
Livongo Health reported a remarkable 115% year-over-year revenue growth for Q1 2020, totaling $68.8 million. Membership for Livongo for Diabetes reached over 328,000, a 100% increase year-over-year. The company raised its full-year revenue guidance to $290 million to $303 million. Despite the strong performance, Livongo noted a GAAP net loss of $5.6 million and adjusted EBITDA ranging from ($14 million) to ($10 million) for 2020. The company also announced a partnership with GEHA to provide services for federal employees.